A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer

International Journal of Cancer

Volumn 135, Issue 11, 2014, Pages 2633-2643

  Barbazan, Jorge ^a   Muinelo Romay, Laura ^a   Vieito, Maria ^a   Candamio, Sonia ^a   Diaz Lopez, Antonio ^b   Cano, Amparo ^b   Gomez Tato, Antonio ^c   De Los Angeles Casares De Cal, Maria ^c   Abal, Miguel ^a   Lopez Lopez, Rafael ^a  

^a Santiago University Clinical Hospital   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Biomarkers; Circulating tumor cells; Epithelial to mesenchymal transition; Metastatic colorectal cancer; Patient outcome; Therapy response

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ISOLATION; CIRCULATING TUMOR CELL; CLINICAL EFFECTIVENESS; CLU GENE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE MARKER; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GAPDH GENE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LOXL3 GENE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PATIENT CODING; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITATIVE ANALYSIS; SURVIVAL TIME; TIMP1 GENE; TREATMENT OUTCOME; VIL1 GENE; ZEB2 GENE; ANALOGS AND DERIVATIVES; BLOOD; CANCER STAGING; COLORECTAL NEOPLASMS; FOLLOW UP; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84921670803     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28910     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA: Cancer J Clin 2011; 61:69-90.
2. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009;9:274-84.
3. Cohen SJ, Punt CJA, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-21.
4. Cohen SJ, Punt CJA, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009;20:1223-9.
5. Gertler R, Rosenberg R, Fuehrer K, et al. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res 2003; 162:149-55.
6. Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000;156:57-63.
7. Ozkumur E, Shah AM, Ciciliano JC, et al. Inertial focusing for tumor antigen-dependent and-inde-pendent sorting of rare circulating tumor cells. Sci Transl Med 2013;5:179ra47-7.
8. Hou HWH, Warkiani MEM, Khoo BLB, et al. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep 2012;3:1259-9.
9. Gervasoni A, Monasterio Munoz RM, Wengler GS, et al. Molecular signature detection of circulating tumor cells using a panel of selected genes. Cancer Lett 2008;263:267-79.
10. Barbazan J, Vieito M, Abalo A, et al. A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer. J Cell Mol Med 2012;16:2342-9.
11. Lagoudianakis EE, Kataki A, Manouras A, et al. Detection of epithelial cells by RT-PCR targeting CEA, CK20, and TEM-8 in colorectal carcinoma patients using OncoQuick density gradient centrifugation system. J Surg Res 2009;155:183-90.
12. Hartkopf AD, Wagner P, Wallwiener D, et al. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res 2011;31:979-84.
13. Hayes DF. Circulating tumor cells at each followup time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006;12:4218-24.
14. Cunningham D, Atkin W, Lenz H-J, et al. Colorectal cancer. The Lancet 2010;375:1030-47.
15. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
16. Aldulaymi B, Bystrom P, Berglund A, et al. High plasma TIMP-1 and serum CEA levels during combination chemotherapy for metastatic colorectal cancer are significantly associated with poor outcome. Oncology 2010;79:144-9.
17. Matsusaka S, Suenaga M, Mishima Y, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. Cancer Sci 2011;102:1188-92.
18. Tol J, Koopman M, Miller MC, et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2010;21:1006-12.
19. Barbazan J, Alonso-Alconada L, Muinelo-Romay L, et al. Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. PLoS ONE 2012;7:e40476.
20. Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development 2012;139:3471-86.
21. Bednarz-Knoll N, Alix-Panabieres C, Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev 2012;31:673-87.
22. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
23. Fabbri F, Carloni S, Zoli W, et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett 2013;335:225-31.
24. Gasch C, Bauernhofer T, Pichler M, et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem 2013;59:252-60.
25. Smirnov DA, Zweitzig DR, Foulk BW, et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005;65:4993-7.
26. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-9.
27. Lankiewicz S, Zimmermann S, Hollmann C, et al. Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Mol Oncol 2008; 2:349-55.
28. Witta SE. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66:944-50.
29. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 30 kinase/AKT pathways. Oncogene 2005;24:7443-54.
30. Yang AD. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006;12:4147-53.
31. Xiong H, Hong J, Du W, et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem 2012;287:5819-32.
32. Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D, et al. A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J 2005;24: 3446-58.
33. Kahlert C, Lahes S, Radhakrishnan P, et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res 2011;17: 7654-63.
34. Comijn J, Berx G, Vermassen P, et al. The twohanded E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001;7:1267-78.
35. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-42.